24 results
8-K
EX-10.2
NBSE
NeuBase Therapeutics Inc
30 Jun 23
NeuBase Announces $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules
4:21pm
or prospects.
(nn) Cybersecurity. (i)(x) There has been no security breach or other compromise of or relating to any of the Company’s or any
8-K
EX-1.1
NBSE
NeuBase Therapeutics Inc
27 Aug 21
Entry into a Material Definitive Agreement
12:00am
of this Agreement by the Company or the sale and delivery by the Company of the Shares.
(qq) Cybersecurity. The Company and its subsidiaries’ information
8-K
EX-10.1
NBSE
NeuBase Therapeutics Inc
30 Jun 23
NeuBase Announces $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules
4:21pm
regarding the Company or its Subsidiaries or their financial results or prospects.
(jj) Cybersecurity. (i)(x) There has been no security breach
424B5
jk1rbb5
30 Jun 23
Prospectus supplement for primary offering
8:42am
424B5
stdxkc1ary0z7
29 Dec 22
Prospectus supplement for primary offering
5:03pm
424B5
respkarebcwzu4oc
23 Apr 21
Prospectus supplement for primary offering
4:05pm
424B5
j7vzfgvogm4g47tx
21 Apr 21
Prospectus supplement for primary offering
4:03pm
424B5
cg18c n09l
27 Aug 21
Prospectus supplement for primary offering
5:21pm
S-4/A
fbnmy0yt
16 Apr 19
Registration of securities issued in business combination transactions (amended)
5:29pm